ZYVERSA THERAPEUTICS, INC. Proceeds from Issuance of Private Placement
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Proceeds from Issuance of Private Placement of $2.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. proceeds from issuance of private placement for the quarter ending 2026-03-31 was $2.00M, a 0.00% change year-over-year.
- ZYVERSA THERAPEUTICS, INC. proceeds from issuance of private placement for the quarter ending 2025-12-31 was -$2.05M.
- ZYVERSA THERAPEUTICS, INC. proceeds from issuance of private placement for the quarter ending 2025-09-30 was $2.05M, a 147.81% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. proceeds from issuance of private placement for the quarter ending 2025-06-30 was $0.00.
- ZYVERSA THERAPEUTICS, INC. proceeds from issuance of private placement for fiscal 2025 was $2.00M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 11 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-13 | -$52.06K derived: sum of 2 quarters · filed 2026-05-13 | $2.00M derived: sum of 3 quarters · filed 2026-05-13 | $2.00M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2025-12-31 | -$2.05M derived: 10-K 12 month − 3 quarters · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $2.00M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $2.05M 10-Q · filed 2025-11-19 | $2.05M derived: sum of 2 quarters · filed 2025-11-19 | $4.05M derived: sum of 3 quarters · filed 2025-11-19 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.00M 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $2.00M 10-Q · filed 2025-11-19 | ||||
| 2024-09-30 | $827.98K 10-Q · filed 2025-11-19 | ||||
| 2022-12-12 | $1.96M 10-K · filed 2024-03-25 | ||||
| 2021-12-31 | $3.18M 10-K · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |